Arthur L Riggs

Author:

Arthur D. Riggs

ISBN #:

0387960384

Author:

Arthur D. Riggs

ISBN #:

0879694904

US Patent:

5047320, Sep 10, 1991

Filed:

Jun 20, 1990

Appl. No.:

7/540876

Inventors:

Hema Pande - Arcadia CA
Arthur D. Riggs - La Verne CA
John A. Zaia - Arcadia CA
Brian R. Clark - Redwood City CA

Assignee:

City of Hope - Duarte CA

International Classification:

C12Q 170
C12Q 168

US Classification:

435 5

Abstract:

A DNA probe has been isolated which is capable of hybridizing to an oligonucleotide sequence coding for a polypeptide from a major 64 Kilodalton protein of human cytomegalovirus (HCMVgp64). The probe has a sequence of at least seventeen (17) to as many as seven hundred twenty-one (721) nucleotides. The probe may be labelled as by radioactivity. The probe has been used to screen DNA fragments constituting a subgenomic library of human cytomegalovirus DNA to obtain DNA fragments coding for the major late protein of human cytomegalovirus. The DNA fragments coding for the major late protein of human cytomegalovirus (HCMVgp64) may be hybridized to DNA fragments of HCMV DNA from an individual having human cytomegalovirus infection. The viral DNA can be used as whole HCMV DNA or as fragments formed by digesting the human cytomegalovirus DNA with a restriction endonuclease such as one of the restriction endonucleases EcoRI, BamHI, XbaI, HindIII and PrtI. During the screening of clinical specimens, the DNA fragment coding for HCMVgp64 of human cytomegalovirus hybridizes to whole HCMV DNA or to a particular one of the DNA fragments produced by digesting the human cytomegalovirus DNA with the restriction endonucleases.

US Patent:

7033763, Apr 25, 2006

Filed:

May 9, 2003

Appl. No.:

10/434369

Inventors:

Qiang Liu - Arcadia CA, US
Steve S. Sommer - Duarte CA, US
Arthur D. Riggs - La Verne CA, US

Assignee:

City of Hope - Duarte CA

International Classification:

C12Q 1/68
C12P 19/34

US Classification:

435 6, 435 911, 435 912

Abstract:

A novel method of pyrophosphorolysis activated polymerization (PAP) has been developed. In PAP, pyrophosphorolysis and polymerization by DNA polymerase are coupled serially for each amplification by using an activatable oligonucleotide P* that has a non-extendible 3′-deoxynucleotide at its 3′ terminus. PAP can be applied for exponential amplification or for linear amplification. PAP can be applied to amplification of a rare allele in admixture with one or more wild-type alleles by using an activatable oligonucleotide P* that is an exact match at its 3′ end for the rare allele but has a mismatch at or rear its 3′ terminus for the wild-type allele. PAP is inhibited by a mismatch in the 3′ specific sequence as far as 16 nucleotides away from the 3′ terminus. PAP can greatly increase the specificity of detection of an extremely rare mutant allele in the presence of the wild-type allele. Specificity results from both pyrophosphorolysis and polymerization since significant nonspecific amplification requires the combination of mismatch pyrophosphorolysis and misincorporation by the DNA polymerase, an extremely rare event.

US Patent:

7238480, Jul 3, 2007

Filed:

Mar 12, 2004

Appl. No.:

10/798844

Inventors:

Qiang Liu - Arcadia CA, US
Steve S. Sommer - Duarte CA, US
Arthur D. Riggs - La Verne CA, US

Assignee:

City of Hope - Duarte CA

International Classification:

C12Q 1/68
C12P 19/34

US Classification:

435 6, 435 911, 435 912

Abstract:

A novel method of pyrophosphorolysis activated polymerization (PAP) has been developed. In PAP, pyrophosphorolysis and polymerization by DNA polymerase are coupled serially for each amplification by using an activatable oligonucleotide P* that has a non-extendible 3′-deoxynucleotide at its 3′ terminus. PAP can be applied for exponential amplification or for linear amplification. PAP can be applied to amplification of a rare allele in admixture with one or more wild-type alleles by using an activatable oligonucleotide P* that is an exact match at its 3′ end for the rare allele but has a mismatch at or near its 3′ terminus for the wild-type allele. PAP is inhibited by a mismatch in the 3′ specific sequence as far as 16 nucleotides away from the 3′ terminus. PAP can greatly increase the specificity of detection of an extremely rare mutant allele in the presence of the wild-type allele. Specificity results from both pyrophosphorolysis and polymerization since significant nonspecific amplification requires the combination of mismatch pyrophosphorolysis and misincorporation by the DNA polymerase, an extremely rare event.

US Patent:

20070298428, Dec 27, 2007

Filed:

Jul 2, 2007

Appl. No.:

11/772622

Inventors:

Qiang Liu - Arcadia CA, US
Steve Sommer - Duarte CA, US
Arthur Riggs - La Verne CA, US

Assignee:

City of Hope - Duarte CA

International Classification:

C12Q 1/68

US Classification:

435006000

Abstract:

A novel method of pyrophosphorolysis activated polymerization (PAP) has been developed. In PAP, pyrophosphorolysis and polymerization by DNA polymerase are coupled serially for each amplification by using an activatable oligonucleotide P* that has a non-extendible 3′-deoxynucleotide at its 3′ terminus. PAP can be applied for exponential amplification or for linear amplification. PAP can be applied to amplification of a rare allele in admixture with one or more wild-type alleles by using an activatable oligonucleotide P* that is an exact match at its 3′ end for the rare allele but has a mismatch at or near its 3′ terminus for the wild-type allele. PAP is inhibited by a mismatch in the 3′ specific sequence as far as 16 nucleotides away from the 3′ terminus. PAP can greatly increase the specificity of detection of an extremely rare mutant allele in the presence of the wild-type allele. Specificity results from both pyrophosphorolysis and polymerization since significant nonspecific amplification requires the combination of mismatch pyrophosphorolysis and misincorporation by the DNA polymerase, an extremely rare event. Using genetically engineered DNA polymerases greatly improves the efficiency of PAP.

US Patent:

55830137, Dec 10, 1996

Filed:

May 2, 1995

Appl. No.:

8/434321

Inventors:

Keiichi Itakura - Arcadia CA
Arthur D. Riggs - La Verne CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C12P 2102
C12N 1570

US Classification:

435 694

Abstract:

The Specification discloses: 1. Recombinant microbial cloning vehicles comprising heterologous DNA coding for the expression of mammalian hormone (e. g. , somatostatin) and other polypeptides, including plasmids suited for the transformation of bacterial hosts. The latter incorporate a regulon homologous to the host in its untransformed state, in reading phase with the structural gene for the heterologous DNA; 2. Cloning vehicles coding for the microbial expression of a protein variously comprising (a) a polypeptide hapten and additional protein sufficient in size to confer immunogenicity on the product of expression, which may find use in raising antibodies to the hapten for assay use or in the manufacture of vaccines; and (b) a desired polypeptide product and additional protein from which the desired product may be cleaved; and 3. Methods of preparing synthetic structural genes coding for the expression of mammalian polypeptides in microbial cloning systems.

US Patent:

50754319, Dec 24, 1991

Filed:

Mar 26, 1991

Appl. No.:

7/671694

Inventors:

John E. Shively - Arcadia CA
Arthur D. Riggs - La Verne CA
Michael Neumaier - Hamburg, DE

Assignee:

City of Hope - Duarte CA

International Classification:

C07H 1700
C12P 2106
C12P 2102
C12P 1934

US Classification:

536 27

Abstract:

A chimeric anti CEA antibody comparable to ATCC Accession No. BH 8747 is described.

US Patent:

52216195, Jun 22, 1993

Filed:

Jan 15, 1992

Appl. No.:

7/821711

Inventors:

Keiichi Itakura - Arcadia CA
Arthur D. Riggs - La Verne CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C12P 2100
C12N 1512
C12N 1570

US Classification:

435 694

Abstract:

The Specification discloses: 1. Recombinant microbial cloning vehicles comprising heterologous DNA coding for the expression of mammalian hormone (e. g. , somatostatin) and other polypeptides, including plasmids suited for the transformation of bacterial hosts. The latter incorporate a regulon homologous to the host in its untransformed state, in reading phase with the structural gene for the heterologous DNA; 2. Cloning vehicles coding for the microbial expression of a protein variously comprising (a) a polypeptide hapten and additional protein sufficient in size to confer immunogenicity on the product of expression, which may find use in raising antibodies to the hapten for assay use or in the manufacture of vaccines; and (b) a desired polypeptide product and additional protein from which the desired product may be cleaved; and 3. Methods of preparing synthetic structural genes coding for the expression of mammalian polypeptides in microbial cloning systems.

US Patent:

50812351, Jan 14, 1992

Filed:

Jul 26, 1989

Appl. No.:

7/385102

Inventors:

John E. Shively - Arcadia CA
Arthur D. Riggs - La Verne CA
Michael Neumaier - Bonn, DE

Assignee:

City of Hope - Duarte CA

International Classification:

C07H 1700

US Classification:

536 27

Abstract:

A chimeric anti CEA antibody comparable to ATCC Accession No. BH 8747 is described.